ClinicalTrials.gg
CompletedNCT02454933CAURALUpdated Sep 19, 2024Results posted

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

A Phase 3 interventional study of AZD9291 and MEDI4736 in Locally Advanced or Metastatic EGFR T790M+ NSCLC, sponsored by AstraZeneca. Completed at 13 sites in 3 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Study summary

A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination with MEDI4736 versus AZD9291 Monotherapy in patients with Locally Advanced or Metastatic Epidermal Growth Factor Receptor T790M mutation-positive Non-Small Cell Lung Cancer who have received Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

Read the detailed description

This a phase III, Multi Centre, Open Label, Randomized, Study to Assess the Efficacy and Safety of AZD9291 (80 mg, orally, once daily) in Combination with MEDI4736 (10 mg/kg (IV) infusion q2w) versus AZD9291 Monotherapy (80 mg, orally, once daily) in patients with a confirmed diagnosis of Epidermal Growth Factor Receptor (EGFR) T790M mutation positive NSCLC, who have progressed following prior therapy with an approved Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) agent. The randomization will be stratified by previous lines of treatment (2nd or 3rd+) and ethnicity (Asian or Non-Asian). A mandatory biopsy will be needed for central testing of T790M mutation status following confirmed disease progression on the most recent treatment regimen. The primary objective of the study is To investigate the safety and tolerability profile of AZD9291 in combination with MEDI4736.

350 patients were originally planned to be evaluated across the two below populations. The recruitment was stopped due to new information on safety of the combination, received from another trial in similar patient population

  1. 2nd line: patients who have progressed following an approved first-line EGFR-TKI treatment but who have not received further treatment.
  2. 3rd line or higher: patients who have progressed following prior therapy with an approved EGFR-TKI and an additional anti-cancer treatment. Patients may have also received additional lines of treatment.
02

Conditions studied

  • Locally Advanced or Metastatic EGFR T790M+ NSCLC

Keywords

  • Phase III Open Label Study; AZD9291 plus MEDI4736 versus AZD9291 Monotherapy; NSCLC After Previous EGFR TKI Therapy; T790M Mutation Positive Tumours.
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged at least 18 years. Japan patients aged at least 20 years.
  • Locally advanced/ NSCLC, not amenable to curative surgery or radiotherapy
  • Confirmation from a previous that the tumour harbours an EGFR mutation known to be associated with EGFR TKI sensitivity
  • Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI. Additional other may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.
  • Patients must have central lab confirmation of tumour T790M status from a biopsy taken after disease progression on the most recent treatment regimen. Only patients with T790M+ will be included in the study
  • At least one lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline as ≥ 10mm in the longest diameter (except lymph nodes which must have short axis ≥ 15mm) with computerised tomography (CT) or magnetic resonance imaging (MRI) which is suitable for accurate repeated measurements
  • World Health Organisation (WHO) performance status 0-1 with no deterioration over the previous 2 weeks and a minimum of 12 weeks
  • Females of using ; negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Treatment with an EGFR-TKI within 5x half-life of study entry; any cytotoxic chemotherapy, agents or other anticancer drugs within 14 days of study entry; current treatment with potent inhibitors/inducers of cytochrome P450 3A4 (); previous treatment with AZD9291 (or other agents specifically targeted against EGFR T790M mutation positive NSCLC); Prior or adjuvant chemotherapy treatment within 6 months of starting 1st EGFR TKI treatment; prior exposure to immune-mediated therapy including, but not limited to, other anti cytotoxic T-lymphocyte-associated antigen 4 (anti ), anti- programmed cell death 1 (anti-PD-1), anti- programmed cell death ligand 1 (anti-PD-L1), and anti-programmed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines; radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks; major surgery within 4 weeks;
  • Current or prior use of medication within 14 days before the first dose of MEDI4736 (excluding intranasal, inhaled, topical , or local steroid injections)
  • Unresolved toxicities from prior therapy
  • History of active primary immunodeficiency
  • Unstable or spinal cord compression
  • Severe/uncontrolled systemic diseases, including uncontrolled hypertension, renal transplant, bleeding diatheses or infection
  • Cardiac disease
  • Ophthalmological conditions
  • nausea/vomiting, chronic gastrointestinal diseases or bowel resection
  • Past history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
  • History of another primary
  • Active or prior documented or inflammatory disorders within the past 3 years prior to the start of treatment
  • History of organ transplant that requires use of immunosuppressive medications
  • Known history of tuberculosis
  • Receipt of live, attenuated vaccine within 30 days prior to the first dose of MEDI4736
  • Inadequate bone marrow reserve or organ function
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    MEDI4736 & AZD9291 Combination

    10mg/kg q2w (IV) infusion \& once daily tablet 80 mg

    Drug: AZD9291 · Drug: MEDI4736

  • Experimental
    AZD9291 Monotherapy

    Once daily tablet 80 mg

    Drug: AZD9291

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Events (AEs) as a Measure of the Safety and Tolerability of Osimertinib in Combination With Durvalumab

    As a measure of the safety and tolerability of osimertinib in combination with durvalumab the number of subjects who experienced any treatment emergent AE (TEAE), any causally related AE, any serious AE (SAE), and any causally related SAE are presented.

    Time frame: From Baseline up to primary analysis data cut-off (up to 24 months).

07

Results

Posted Aug 10, 2018
Limitations and caveats
Subject enrolment was terminated early on 29 September 2015 after higher than anticipated incidence of interstitial lung disease-like events in subjects receiving osimertinib + durvalumab in a separate Phase Ib open-label study D5160C00006 (TATTON).

Participant flow

Subjects were recruited to this study in 9 centres in South Korea, Canada and Taiwan. First subject first visit: 26 August 2015.

Participant flow — Overall Study
MilestoneOsimertinib 80 mgOsimertinib 80 mg + Durvalumab 10 mg/kg
Started1712
Treatment group randomised to1514
Ongoing at primary analysis data cut-off94
Completed51
Not completed1211
Withdrew: Progressive disease107
Withdrew: Adverse event11
Withdrew: Withdrawal by subject03
Withdrew: Lost to follow-up10

Outcome measures

PrimaryNumber of Subjects With Adverse Events (AEs) as a Measure of the Safety and Tolerability of Osimertinib in Combination With Durvalumab

As a measure of the safety and tolerability of osimertinib in combination with durvalumab the number of subjects who experienced any treatment emergent AE (TEAE), any causally related AE, any serious AE (SAE), and any causally related SAE are presented.

Time frame:
From Baseline up to primary analysis data cut-off (up to 24 months).
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events (AEs) as a Measure of the Safety and Tolerability of Osimertinib in Combination With Durvalumab
ParticipantsOsimertinib 80 mg + Durvalumab 10mg/kg
Any AE12
Any AE causally related to treatment8
Any AE causally related to osimertinib only8
Any AE causally related to durvalumab only4
Any AE causally related to osimertinib+durvalumab3
Any SAE3
Any SAE causally related to treatment1

Adverse events

Collected over TEAEs are presented from the date of first dose and up to and including 30 days following the date of the last dose of osimertinib or 90 days following the date of last dose of durvalumab (up to approximately 31 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Osimertinib 80 mg4/17 (23.5%)6/17 (35.3%)17/17 (100%)
Osimertinib 80 mg + Durvalumab 10 mg/kg8/12 (66.7%)3/12 (25%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventOsimertinib 80 mgOsimertinib 80 mg + Durvalumab 10 mg/kg
PneumoniaInfections and infestations3/170/12
Oedema peripheralGeneral disorders0/171/12
MyopathyMusculoskeletal and connective tissue disorders0/171/12
HeadacheNervous system disorders0/171/12
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/171/12
DiarrhoeaGastrointestinal disorders1/170/12
VomitingGastrointestinal disorders1/170/12
PyrexiaGeneral disorders1/170/12
Urinary tract infectionInfections and infestations1/170/12
Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/170/12
Most frequent other events
Showing 10 of 157
Most frequent other events
EventOsimertinib 80 mgOsimertinib 80 mg + Durvalumab 10 mg/kg
DiarrhoeaGastrointestinal disorders8/176/12
Decreased appetiteMetabolism and nutrition disorders2/176/12
PruritusSkin and subcutaneous tissue disorders4/175/12
ParonychiaInfections and infestations7/172/12
Dermatitis acneiformSkin and subcutaneous tissue disorders7/172/12
ConstipationGastrointestinal disorders3/174/12
CoughRespiratory, thoracic and mediastinal disorders4/174/12
Dry skinSkin and subcutaneous tissue disorders3/174/12
StomatitisGastrointestinal disorders5/170/12
ArthralgiaMusculoskeletal and connective tissue disorders5/172/12

Baseline characteristics

The safety analysis set consisted of all subjects who received at least one dose of randomised treatment.

Age, Continuous
Age, Continuous(years)Osimertinib 80 mgOsimertinib 80 mg + Durvalumab 10mg/kgTotal
Mean62.3 ± 10.657.6 ± 11.260.3 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Osimertinib 80 mgOsimertinib 80 mg + Durvalumab 10mg/kgTotal
Female13619
Male4610
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Osimertinib 80 mgOsimertinib 80 mg + Durvalumab 10mg/kgTotal
Hispanic or Latino101
Not Hispanic or Latino161228
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Osimertinib 80 mgOsimertinib 80 mg + Durvalumab 10mg/kgTotal
American Indian or Alaska Native000
Asian151126
Native Hawaiian or Other Pacific Islander000
Black or African American000
White213
More than one race000
Unknown or Not Reported000
08

Study locations

13 sites
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Busan, 47392, Korea, Republic of
  • Research Site
    Daegu, 42601, Korea, Republic of
  • Research Site
    Incheon, 21565, Korea, Republic of
  • Research Site
    Jinju-si, 660-702, Korea, Republic of
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 03181, Korea, Republic of
  • Research Site
    Seoul, 156-707, Korea, Republic of
  • Research Site
    Ulsan, 44033, Korea, Republic of
  • Research Site
    Kaohsiung, 82445, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2015 to primary completion in Aug 2017, 25 months.

Results were first posted in Aug 2018, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2015
First posted
May 27, 2015
StartActual
Jul 15, 2015
Primary completionActual
Aug 21, 2017
CompletionActual
Jun 21, 2023
Results first posted
Aug 10, 2018
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02454933
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 27, 2015
Start date
Jul 15, 2015
Primary completion
Aug 21, 2017
Completion
Jun 21, 2023
Results posted
Aug 10, 2018
Last update
Sep 19, 2024

Study contacts

Leora Horn, MD
principal investigator · Vanderbilt University, Nashville, USA
James CH Yang, MD
principal investigator · National Taiwan University Hospital, Taiwan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Osimertinib · Durvalumab

Start the discussion